INTRODUCTION
============

Photodynamic therapy (PDT) uses photosensitizer drugs that are activated by light energy and are then able to interact with oxygen or other vascular and cellular components to stimulate a photodynamic reaction often producing damage or necrosis to the target tissue. This treatment effect occurs in all sensitized cells (such as normal esophageal mucosa, as well as dysplastic or neoplastic mucosa) that are exposed to a light source, in proportion of the mucosal concentration of the photosensitizer drug (often determined by mucosal blood flow and oxygenation status) and dose of light energy. PDT has been used for decades to treat diseased esophageal mucosa in the setting of squamous dysplasia and carcinoma, as well as Barrett\'s mucosa with dysplasia or neoplasia.[@B1]

Many agents have been used as photosensitizers in esophageal disease. The initial studies were focused on patients with esophageal cancer and the use of porfimer sodium (Ps) PDT.[@B2],[@B3] Such research led to approval of PDT in the United States, Europe, and Japan. Later, Overholt et al.[@B4],[@B5] published a landmark study on the use of Ps PDT and patients with Barrett\'s esophagus (BE) with high grade dysplasia (HGD). This trial was a prospective, randomized, controlled, multicenter study and results of the study were published in three major research articles.[@B4],[@B5] The trial showed a lower progression rate to invasive esophageal carcinoma among patients who were treated with PDT. Since then, several studies demonstrated the clinical usefulness of Ps PDT on BE patient with dysplasia and neoplasia which has resulted in the development of other photosensitizers ([Table 1](#T1){ref-type="table"}).[@B6]-[@B15]

The initial description of PDT using porphyrin-based agents, hematoporphyrin derivative (HpD) and dihematoporphyrin ether (DHE) in combination with red light, became the predominant forms of PDT.[@B16] After further purification of the photosensetizers, several agents were released: Ps (Photofrin; Pinnacle Biologics Inc., Bannockburn, IL, USA),[@B17] DHE (available in Europe under the trade name Photosan \[Seehof Laboratories, Wesselburen, Germany\], a second-generation form of HpD available in China under the trade name Hemporfin \[hematoporphyrin monomethyl ether; Funda-Zhangjiang Bio-Pharmaceutical, Shanghai, China\]).[@B18] Ps has recently undergone pharmacokinetic studies after repeated administration (demonstrating prolonged half-life and delayed excretion after repeated infusion).[@B19] A recent review from Nara, Japan, has also described advances in the research and development of 5-aminolevulinic acid (ALA) for PDT, as well as the use of nonporphyrinoid compounds.[@B20]

When reviewing the literature about PDT, one needs to pay attention to three major points of interest. First of those points is the disease status of the study population. The results of a study on patient with BE and low grade dysplasia (LGD) should be interpreted differently from that of patients with HGD or early carcinoma (EC) and squamous dysplasia or carcinoma. Second, one requires a basic understanding of the physics and mechanics of the PDT technique. This includes how different photosensitizers are used, the various light sources, and the routes of administration. Equivalent doses of various agents may result in varying depth of tissue necrosis even if the source of energy is constant.[@B21]-[@B25] Similarly, varying the light source, and wavelengths, will result in varying penetration into esophageal tissue. For example, red light (630 nm) seems to penetrate esophageal mucosa deeper than green light (532 nm).

Lastly, one needs to understand the ablative modalities used in a given study. Most regulatory trials allow the use of PDT only. On the other hand, clinical series seem to use additional ablative modalities, like radiofrequency energy or argon plasma coagulation (APC), to ablate residual BE after the initial PDT treatment. Such use, though appropriate,[@B26] may introduce bias into the final conclusions of a study unless clearly accounted for by the authors.

DETECTION OF ESOPHAGEAL DYSPLASIA
=================================

Dr. Norman Barrett initially described BE, intestinal metaplasia of the esophagus, in the 1950s. Since then, the link between BE and esophageal adenocarcinoma has been extensively studied and well established.[@B27],[@B28] The incidence of esophageal cancer is on the rise.[@B29],[@B30] The development of esophageal adenocarcinoma among patients with BE seems to follow an established pathway through LGD, HGD, then adenocarcinoma. Therefore, detecting and treating dysplasia is of critical importance. Yet, dysplasia can be hard to detect in white light endoscopy (WLE). Therefore, a protocol was established to perform four-quadrant biopsy every 1 to 2 cm of BE (Seattle protocol). This, however, is cumbersome, and many clinicians do not adhere to such protocol resulting in many false negative screening. Therefore, many studies have evaluated the use of chromoendoscopy (CE) to detect dysplasia in BE. CE uses various dyes (indigo carmine, methylene blue, acetic acid, etc.) to highlight vascular patterns on surface mucosa. This enables the endoscopist to perform targeted biopsies of suspicious areas and increases the yield for dysplasia. Virtual chromoendoscopy (VE) uses various light sources and lenses on the endoscope in order to highlight the surface vasculature.

Both methods have been extensively studied in patients with BE. We recently assessed the increase in the diagnostic yield in detecting dysplasia using VE and CE compared to WLE with random biopsies in a meta-analysis. The study has been submitted for publication and an abstract form has been submitted to Digestive Disease Week 2013. We found that using either CE or VE increases the yield of detecting dysplasia by 34% (95% confidence interval, 20% to 56%, *p*=0.0001). This study, among others, highlights the importance of improved endoscopic imaging, which will be required to detect and treat patients with Barrett\'s dysplasia.

WHY PDT IN ESOPHAGEAL DISEASE?
==============================

As discussed earlier, PDT offers different tissue penetration depending on the agent and the wavelength of the light source. In the esophagus, PDT offers clear advantages by allowing targeted therapy to the affected area using endoscopy. By controlling the depth of tissue necrosis, one can ensure eradication of Barrett\'s mucosa while minimizing the risk of esophageal perforation.[@B31]

In early clinical studies, surgeons and gastroenterologists used Ps combined with red light for palliation of obstructing lesions, as well as for curative treatment of early cancers. As clinicians became more comfortable with the technique, and with continued improvements in endoscopic light dosimetry, the uses of sodium porfimer PDT expanded to esophageal dysplasia (BE and squamous disease). As a result, Ps has been extensively studied in the United States and North America. The efficacy of this form of PDT in eradicating esophageal dysplasia has been documented in large prospective studies.[@B5],[@B12]

Ps, however, is a first generation agent that has some shortcomings. Ps is not specific to mucosa. In addition, it causes prolonged photosensitivity, lasting up to 6 weeks, which can cause significant skin damage if a patient is exposed to light. Therefore, new photosensitizers have been produced to overcome those issues. One of such agents is metatetrahydroxy-phenyl chlorine (mTHPC, temoporfin, Foscan; Biolitec AG, Jena, Germany). The mTHPC is more potent compared to sodium porfimer, requires a smaller dosage and lower light energy. The mTHPC shortens the period of photosensitivity to 2 to 3 weeks. Yet, it seems to be associated with an increased risk of perforation and stricture formation compared to sodium porfimer.[@B32] ALA is another photosensitizer which works on mucosal cells only.[@B33] ALA allows targeted necrosis of mucosal cells only, thus preventing damage to submucosal tissue. In theory, this should lead to decreased risk of perforation and stricture formation.[@B25] A recent trial from University College London sought to randomize 128 patients with Barrett\'s HGD to PDT using 5-ALA or Ps. Over the study period from 2006 to 2009, 64 patients were actually randomized to PDT with complete response for HGD in 16/34 patients in the ALA group (47%) and 12/30 patients in the Ps group (40%). The overall cancer incidence was 14% (nine/64 patients) that was usually treated with additional PDT or EMR plus chemo-radiation therapy. At a median 2 year follow-up, there was no statistically significant difference in outcome of PDT using either 5-ALA or Ps. A subgroup analysis suggested that patients with BE segments less than 6 cm length had improved outcomes with low risk of stricture or death after 5-ALA PDT.[@B34] Several other agents have been studied as photosensitizers in PDT. Those are summarized in [Table 1](#T1){ref-type="table"}, after Yano et al.[@B20]

PHOTOSENSITIZING AGENTS
=======================

Porfimer sodium (Ps)
--------------------

As mentioned earlier, Ps is the most widely used agent for esophageal PDT. It is administered by intravenous injection. This chemical is a HpD and was first approved in the United States in 1995 for use among patient with advanced esophageal carcinoma.[@B35] The best study on sodium porfimer PDT came from Overholt et al.[@B35] who introduced cylindrical inflatable balloon which is used to administer light to 101 patients with HGD. Patients were then followed up for 4 years showing a resolution of HGD in 54% complete remission of intestinal metaplasia (CRIM). Among patients with LGD, success rate was 93%. The success rate for HGD and cancer were noted to be 78% and 48%. In those patients, stenosis was noted in 30% of all patients. A larger (208 patients), multicenter study by Overholt et al.[@B35] later showed complete eradication of HGD in 77% versus 39% among patients who had PDT and control respectively. This response was still present at 5 years of follow-up.

Since then, several other centers have reported clinical results of PDT. We reported our experience in 102 patients with BE and HGD/EC.[@B11],[@B36]-[@B38] After a mean follow-up of 18 months, a single session of Ps PDT showed CRIM in 56% of patients.[@B38] We also reviewed the combined experience of Mayo Clinic in Jacksonville and Rochester. One hundred and forty-two patients with BE and HGD were treated with sodium porfimer PDT. At 19 months of follow-up, CRIM was noted in 50% of patients in Jacksonville compared to 35% in Rochester.[@B39],[@B41] HGD was eliminated in 100% in Jacksonville, and 80% in Rochester. Esophageal strictures were noted in 20% of patients in Jacksonville and 27% of patients in Rochester.

Stricture formation is one of the most common complications post PDT. Panjehpour et al.[@B41],[@B42] looked at the effect of oral steroids post PDT on stricture formation. Sixty patients with BE and HGD were randomized to be treated with either PDT alone or PDT combined with oral prednisone. Surprisingly, the results showed a trend towards more stricture formation in the prednisone group compared (29% vs. 16%); yet this did not reach statistical significance.[@B41],[@B42]

ALA
---

As previously mentioned, ALA is another photosensitizing agent that has been used in PDT. ALA is a pro-drug which stimulates the endogenous production of protoporphyrin IX within the gut mucosa.[@B43],[@B44] ALA compounds have been used in Europe of several years. A commercially available form of ALA, Levulan, was approved by the US Food and Drug Administration.[@B45] ALA is usually activated by red light and was expected to offer several advantages including a shorter photosensitivity period of 1 to 2 days and the preferential targeting of the superficial mucosal layer.[@B46]-[@B49]

The initial studies on ALA PDT were encouraging.[@B50]-[@B53] Most notably, Ackroyd et al.[@B54],[@B55] conducted a double-blinded, randomized, placebo-controlled clinical trial among patients with BE and LGD using ALA PDT. After a mean follow-up of 24 months, complete remission of dysplasia was achieved in 98% of patients.[@B54],[@B55]

Pech et al.[@B56] used ALA PDT to treat 35 patients with BE with HGD and reported a very high complete response rate of 97% of patients after mean follow-up of 42 months. Since then, several other studies have been published with similar results.[@B56]-[@B59]

Despite the encouraging results of those studies, orally-administered ALA was found to be associated with significant side effects including elevated liver enzyme tests, chest pain, neuropathy, and sudden death.[@B60] To avoid such toxicity, Ortner et al.[@B61] administered ALA topically using a spray catheter at the time of endoscopy. This was used to treat seven patient with BE and seven patients with BE and LGD.[@B61] The results of this study showed progression from BE to HGD in one patient and CRIM in only 21% of patients. Hence, this form of using ALA was abandoned. As discussed above, at a median 2 year follow-up, there was no statistically significant difference in outcome of PDT using either 5-ALA or Ps. However, a subgroup analysis suggested that patients with BE segments less than 6 cm length had improved outcomes with low risk of stricture or death after 5-ALA PDT.[@B34]

In addition to the above shortcomings, ALA PDT appears to perform poorly when compared to other ablation methods. In a study by Ragunath et al.,[@B62] ALA PDT was compared to APC in 26 patients with BE with dysplasia. The authors found that APC was more effective, safer, and less expensive compared to ALA PDT. Other authors have reproduced these results.[@B54],[@B63],[@B64] Therefore, the correct ALA dose and the optimal light dose have not been established and further studies need to be conducted before this form of PDT can be recommended as first line for Barrett\'s ablation.

mTHPC
-----

As discussed earlier, mTHPC, a chlorine derivative, is a potent photosensitizer. It has a shorter period of photosensitivity compared to sodium porfimer and requires less light and lower drug doses to produce the effect. The use of mTHPC has been limited due to reported cases of tissue necrosis among patients with head and neck cancer.[@B65] The use of mTHPC in patients with BE has been limited to a small number of studies ([Table 2](#T2){ref-type="table"}). The optimal light settings and drug dosimetry are not known. Further studies may be needed to optimize treatment parameters for mTHPC PDT in patients with BE.

LIGHT DOSIMETRY AND DELIVERY
============================

At its core, PDT works by sensitizing esophageal mucosa to light. Therefore, the method by which light is delivered is of great importance to the success of this therapy. There is no easy way to determine the ideal dosage of light for any given patients. Too much light may lead to tissue necrosis and stricture formation. Too little light means incomplete eradication of dysplasia or BE. In addition to finding the right dosage, one has to overcome the uneven exposure to light caused by esophageal folds. Due to peristalsis and respiratory motion, maintaining central positioning of the light sources can be a challenge.[@B50] The light delivery system is usually composed of a modified diffuser. One way to overcome this was the creation of an elastic catheter balloon.[@B66] This allowed better centering the fiber and more equal distribution of light to the treatment area. However, over-distention of the esophageal wall may result in decreased mucosal perfusion leading to decreasing effectiveness.[@B66],[@B67] In addition to the balloon, another group of researchers used a large diameter rigid light distributor to improve light delivery.[@B68] The use of advanced optical techniques, such as fluorescence spectroscopy or optical coherence tomography, may help assess drug levels at the level of the mucosa and the progression of the photodynamic reaction to improve PDT outcomes.[@B69]-[@B71] The development of improved light dosimetry and delivery system will be crucial to the future of PDT and will determine if PDT can remain a viable endoscopic mucosal ablation treatment option.[@B72]-[@B74]

PDT has been particularly promising in patients with advanced esophageal carcinoma that was unsuitable for surgery, or for persistent/recurrent disease after chemoradiation therapy (CRT). Yano et al.[@B20] performed Ps-PDT as salvage treatment in patients with recurrent disease after CRT with promising results. Subsequently, a phase I/II study is being conducted using PDT with talaporfin sodium in patients with recurrent disease after CRT for esophageal carcinoma in Japan.[@B20] Lindenmann has also reported the salvage or palliative use of Ps PDT to prolong survival in patients with persistent/recurrent disease after CRT for esophageal cancer.[@B75]

ENDOSCOPIC MUCOSAL RESECTION (EMR)
==================================

EMR uses diathermy snare to resect nodular, dysplastic, or neoplastic esophageal lesions. EMR is used for staging of esophageal neoplasia but can also be used for curative intent.[@B76] There are several EMR techniques. The most common includes using the multiband mucosectomy method with or without saline injection lift to remove the most suspicious lesions (DT-6-5F; Cook Medical, Bloomington, IN, USA). This involves placement of a rubber band around the suspicious lesion followed by resection of the area using a snare. For larger lesions, the area is lifted by injection of fluid, which can vary by different endoscopists. A cap is used to suction the mucosa while a snare is used to resect the affected area (K-008; Olympus America Inc., Center Valley, PA, USA). This is repeated multiple times until the whole lesion has been resected.

Several studies have established the utility of EMR, with or without ablation therapy, for treatment of EC and HGD in patients with BE.[@B77]-[@B80] When EMR is done on focal lesions, Barrett\'s mucosa is still present and dysplasia or neoplasia can recur. There are two schools of thought regarding the eradication of BE. The traditional approach has been to use ablation after EMR with the goal of achieving CRIM.

Complete Barrett\'s eradication is a subset of EMR in which the whole BE mucosa is resected endoscopically. In doing so, there is no need for ablative therapies including PDT. Satodate et al.[@B81] first described this approach as a case report in 2003. Since then, other investigators have studied and advocated for this approach. Using this approach, studies have shown the rate of CRIM to be 86% to 100%. The main limitation for this approach is the high rate of dysphagia due to stenosis (up to 50%). This approach continues to be a viable alternative to patients who do not undergo ablative therapies including PDT.[@B80],[@B82]-[@B84]

OTHER ABLATIVE MODALITIES
=========================

Besides PDT, other ablative therapies are used for this purpose. This includes radiofrequency ablation (RFA), cryotherapy, and APC.[@B85]-[@B87] The most commonly used of those is RFA using the HALO system (MARRX Medical Inc., Sunnyvale, CA, USA). RFA can be applied locally or circumferentially. Under standard settings, the depth of penetration is 500 to 1,000 µm. The most important study on RFA came by Shaheen et al.[@B87] This was a multicentered, randomized, controlled clinical trial of 127 patients with Barrett\'s dysplasia. Patients were randomized to RFA or sham endoscopic therapy in a 2:1 ratio. The final results showed CRIM in 77.4% of RFA group compared to 2.3% in the control group (*p*\<0.0001). Progression to cancer was seen in 1.2% in the RFA group compared to 9.3% in the control group (*p*\<0.05). In addition, RFA has had a low rate of stenosis of less than 3% and perforation seems to occur in less than 0.2% of patients.[@B88],[@B89]

CONCLUSIONS
===========

For many years, PDT became an important method for mucosal ablation in patients with BE and squamous dysplasia and carcinoma. Ps PDT has been shown to be a safe and reliable treatment method for eliminating dysplasia and preventing the development of esophageal cancer. The technique seems to have the advantage of selectively targeting mucosal layer while minimizing stricturing and perforation. However, significant drawbacks to PDT have caused a decrease in the use of this method compared to RFA. These include the need for IV administration agents and extended periods of photosensitization. Newer photosensitizing agents and more sophisticated light dosimetry will be needed to bring PDT back to mainstream ablative therapy in gastroenterology.
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HpD, hematoporphyrin derivative; DHE, dihematoporphyrin ether; HMME, hematoporphyrin monomethyl ether; ALA, aminolevulinic acid; mTHPC, meso-tetrahydroxyphenyl chlorine; NPe6, mono-L-aspartyl chlorine e6; SnEt2, tin-etio-purpurin; LED, light emitting diode; Pc4, phthalocyanine; AISPc, aluminum disulphonated phthalocyanine; AIPcS4, aluminum phthalocyanine tetrasulfonate; BPD, benzoporphyrin derivative; BPDMA, benzoporphyrin derivative monoacid; HPPH, 2-\[1-hexyloxyethyl\]2-devinyl-pyropheophorbide-a.
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BE, Barrett\'s esophagus; HGD, high grade dysplasia; AC, adenocarcinoma.
